NASDAQ:SGTX

Sigilon Therapeutics Stock Forecast, Price & News

$34.50

-0.09 (-0.26 %)

(As of 01/21/2021 12:00 AM ET)

Add

Compare

Today's Range

$33.91

Now: $34.50▼

$35.04

50-Day Range

$27.60

MA: $35.92▼

$48.03

52-Week Range

$22.00

Now: $34.50▼

$54.32

Volume57,987 shs

Average Volume107,784 shs

Market Capitalization$1.04 billion

P/E RatioN/A

Dividend YieldN/A

BetaN/A

Sigilon Therapeutics, Inc., a biopharmaceutical company, develops functional cures for patients with chronic diseases. Its lead product candidate is SIG-001, which is in Phase I/II clinical trial to prevent bleeding episodes in patients with moderate-severe to severe Hemophilia A. The company is also developing SIG-005 to treat the non-neurological manifestations of the disease in patients with mucopolysaccharidosis type 1; and SIG-002 designed to replace islet cells for the treatment of type 1 diabetes. The company was formerly known as Sigilon, Inc. and changed its name to Sigilon Therapeutics, Inc. in June 2017. Sigilon Therapeutics, Inc. was founded in 2015 and is headquartered in Cambridge, Massachusetts.

Overall MarketRank^™

1.89 out of 5 stars

Medical Sector

88th out of 1,926 stocks

3.4 Analyst's Opinion

Consensus Rating
Sigilon Therapeutics has received a consensus rating of Buy. The company's average rating score is 2.75, and is based on 3 buy ratings, 1 hold rating, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $53.75, Sigilon Therapeutics has a forecasted upside of 55.8% from its current price of $34.50.
Amount of Analyst Coverage
Sigilon Therapeutics has only been the subject of 4 research reports in the past 90 days.

3.8 Community Rank

Outperform Votes
Sigilon Therapeutics has received 3 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
Sigilon Therapeutics has received 1 “underperform” votes. (Add your “underperform” vote.)
Community Sentiment
Sigilon Therapeutics has received 75.00% “outperform” votes from our community.

MarketBeat's community ratings are surveys of what our community members think about Sigilon Therapeutics and other stocks. Vote “Outperform” if you believe SGTX will outperform the S&P 500 over the long term. Vote “Underperform” if you believe SGTX will underperform the S&P 500 over the long term. You may vote once every thirty days.

0.0 Dividend Strength

Dividend Yield
Sigilon Therapeutics does not currently pay a dividend.
Dividend Growth
Sigilon Therapeutics does not have a long track record of dividend growth.

1.7 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Sigilon Therapeutics insiders have bought more of their company's stock than they have sold. Specifically, they have bought $5,400,000.00 in company stock and sold $0.00 in company stock.

0.6 Earnings and Valuation

Earnings Growth
Earnings for Sigilon Therapeutics are expected to grow in the coming year, from ($3.60) to ($2.14) per share.

See Top Rated MarketRank™ Stocks Here

Industry, Sector and Symbol

Stock Exchange NASDAQ

Industry N/A

Sub-IndustryN/A

SectorMedical

Current SymbolNASDAQ:SGTX

Previous Symbol

CUSIPN/A

CIKN/A

Websigilon.com

Phone617-336-7540

EmployeesN/A

Debt

Debt-to-Equity RatioN/A

Current RatioN/A

Quick RatioN/A

Price-To-Earnings

Trailing P/E RatioN/A

Forward P/E RatioN/A

P/E GrowthN/A

Sales & Book Value

Annual SalesN/A

Price / SalesN/A

Cash FlowN/A

Price / Cash FlowN/A

Book ValueN/A

Price / BookN/A

Profitability

EPS (Most Recent Fiscal Year)N/A

Net IncomeN/A

Net MarginsN/A

Return on EquityN/A

Return on AssetsN/A

Miscellaneous

Outstanding Shares30,190,000

Market Cap$1.04 billion

Next Earnings DateN/A

OptionableNot Optionable

$34.50

-0.09 (-0.26 %)

(As of 01/21/2021 12:00 AM ET)

30 days | 90 days | 365 days | Advanced Chart

Receive SGTX News and Ratings via Email

Sign-up to receive the latest news and ratings for SGTX and its competitors with MarketBeat's FREE daily newsletter.

Sigilon Therapeutics (NASDAQ:SGTX) Frequently Asked Questions

Is Sigilon Therapeutics a buy right now?

4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Sigilon Therapeutics in the last year. There are currently 1 hold rating and 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Sigilon Therapeutics stock.
View analyst ratings for Sigilon Therapeutics or view MarketBeat's top 5 stock picks.

What stocks does MarketBeat like better than Sigilon Therapeutics?

Wall Street analysts have given Sigilon Therapeutics a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Sigilon Therapeutics wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

What is Doug Parker's approval rating as Sigilon Therapeutics' CEO?

1,448 employees have rated Sigilon Therapeutics CEO Doug Parker on Glassdoor.com. Doug Parker has an approval rating of 60% among Sigilon Therapeutics' employees. This puts Doug Parker in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

What price target have analysts set for SGTX?

4 brokerages have issued 1-year price objectives for Sigilon Therapeutics' stock. Their forecasts range from $45.00 to $62.00. On average, they anticipate Sigilon Therapeutics' stock price to reach $53.75 in the next year. This suggests a possible upside of 55.8% from the stock's current price.
View analysts' price targets for Sigilon Therapeutics or view Wall Street analyst' top-rated stocks.

Who are some of Sigilon Therapeutics' key competitors?

Some companies that are related to Sigilon Therapeutics include STAAR Surgical (STAA), Progyny (PGNY), Hypera (HYPMY), Convatec Group Plc (CTEC.L) (CTEC), Arvinas (ARVN), Immunovant (IMVT), FibroGen (FGEN), Abcam (ABCZY), Glaukos (GKOS), National Vision (EYE), Editas Medicine (EDIT), Dechra Pharmaceuticals PLC (DPH.L) (DPH), MorphoSys (MOR), SpringWorks Therapeutics (SWTX) and BTG (BTGGF).
View all of SGTX's competitors.

Who are Sigilon Therapeutics' key executives?

Sigilon Therapeutics' management team includes the following people:

Dr. Rogerio Vivaldi Coelho M.B.A., Pres, CEO & Director (Age 57, Pay $723.21k)
Dr. Robert S. Langer Jr., Co-Founder & Member of Scientific Advisory Board (Age 72, Pay $150k)
Dr. Daniel G. Anderson Ph.D., Co-Founder, Director & Member of Scientific Advisory Board (Age 52, Pay $150k)
Mr. Glenn M. Reicin M.B.A., CFO & Treasurer (Age 57, Pay $416.7k)
Dr. Devyn Smith Ph.D., Chief Operating Officer (Age 50, Pay $462.33k)
Dr. Omid Veiseh Ph.D., Co-Founder
Dr. Arturo Vegas Ph.D., Co-Founder
Dr. David Peritt, Chief Technology Officer (Age 57)
Mr. Matthew Kowalsky J.D., Chief Legal Officer (Age 49)

When did Sigilon Therapeutics IPO?

(SGTX) raised $101 million in an initial public offering (IPO) on Friday, December 4th 2020. The company issued 5,600,000 shares at $17.00-$19.00 per share. Morgan Stanley, Jefferies, Barclays and Canaccord Genuity served as the underwriters for the IPO.

What is Sigilon Therapeutics' stock symbol?

Sigilon Therapeutics trades on the NASDAQ under the ticker symbol "SGTX."

When did Sigilon Therapeutics' quiet period expire?

Sigilon Therapeutics' quiet period expired on Wednesday, January 13th. Sigilon Therapeutics had issued 7,000,000 shares in its IPO on December 4th. The total size of the offering was $126,000,000 based on an initial share price of $18.00. During Sigilon Therapeutics' quiet period, insiders and any underwriters that worked on the IPO were restricted from issuing any research reports for the company because of regulations issued by the Securities and Exchange Commission. Now that the company's quiet period has ended, brokerages that served as underwriters are now able to initiate research on the company.

How do I buy shares of Sigilon Therapeutics?

Shares of SGTX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Sigilon Therapeutics' stock price today?

One share of SGTX stock can currently be purchased for approximately $34.50.

How big of a company is Sigilon Therapeutics?

Sigilon Therapeutics has a market capitalization of $1.04 billion.

What is Sigilon Therapeutics' official website?

The official website for Sigilon Therapeutics is sigilon.com.

How can I contact Sigilon Therapeutics?

The company can be reached via phone at 617-336-7540.

This page was last updated on 1/22/2021 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Sigilon Therapeutics Stock Forecast, Price & News

Adding

Adding

Adding Sigilon Therapeutics, Inc.

MarketRank™

Overall MarketRank™